Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126940741 | 12694074 | 1 | I | 20130502 | 20160816 | 20160829 | 20160829 | EXP | FR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-068380 | BRISTOL MYERS SQUIBB | 79.93 | YR | M | Y | 0.00000 | 20160829 | CN | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126940741 | 12694074 | 1 | PS | COUMADINE | WARFARIN SODIUM | 1 | Oral | Y | 9218 | TABLET | |||||||||
| 126940741 | 12694074 | 2 | SS | LOVENOX | ENOXAPARIN SODIUM | 1 | Oral | UNK | Y | 0 | |||||||||
| 126940741 | 12694074 | 3 | SS | KARDEGIC | ASPIRIN LYSINE | 1 | Oral | UNK | Y | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126940741 | 12694074 | 1 | Atrial fibrillation |
| 126940741 | 12694074 | 2 | Product used for unknown indication |
| 126940741 | 12694074 | 3 | Cerebrovascular accident |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126940741 | 12694074 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126940741 | 12694074 | Haemoptysis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126940741 | 12694074 | 2 | 201304 | 20130502 | 0 | |
| 126940741 | 12694074 | 3 | 20130502 | 0 |